Journal: The Journal of Gene Medicine

Article Title: Development of CpG‐Depleted CFTR Plasmid‐Based Nanoparticles for Nonviral Gene Therapy in Lung Cystic Fibrosis Disease

doi: 10.1002/jgm.70087

Figure Lengend Snippet: CFTR plasmids construction using different promoters. (a) Schematic representation of the workflow for constructing R6K‐hCMV‐OP‐ CFTR plasmids derived from the R6K‐hCEFIα‐OP‐ CFTR plasmid. (b) Verification of plasmid constructs by cutting R6K‐hCEFIα‐OP‐ CFTR and R6K‐hCMV‐OP‐ CFTR plasmids using SbfI and HindIII restriction enzymes to confirm the hCMV enhancer and hEFIα promoter (hCEFIα) (536 bp) and hCMV enhancer and hCMV promoter (516 bp) bands. Confirmation of the plasmid sizes for R6K‐hCEFIα‐OP‐ CFTR (7369 bp) and R6K‐hCMV‐OP‐ CFTR (7349 bp) was achieved by using the HindIII restriction enzyme.

Article Snippet: The hCMV promoter sequence was obtained from the RG216476 plasmid and purchased from Origene (Rockville, MD, USA).

Techniques: Derivative Assay, Plasmid Preparation, Construct